ATHA: Athira Pharma Corp Growth-Adjusted Payback Ratio
Athira Pharma, Inc. (ATHA) focuses on developing neurodegeneration drugs in Washington state. The PEG ratio trend on this GURU.Markets chart visualizes the performance of these centers, where 0.00 indicates the value of this parameter. The business remains resilient to market volatility, leveraging the success of clinical trials, while the company delegates production and complex formulas to external contractors.
Athira Pharma, Inc. (ATHA) - metric breakdowns and financial figures
- stock quotes and analyst forecast:
- market capitalization information:
- book capitalization indicators:
- debt obligations and liquidity statistics:
Total Debt to Capital Athira Pharma, Inc.|ATHA - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital athira.com|ATHA - Company Debts|Debts to Book Capitalization Ratio Athira|ATHA - Company Long-Term Debts|Company Short-Term Loans and Borrowings Athira Pharma|Quick Ratio athira.com
- net income and valuation ratios data:
ATHA - Company Net Income|Expected Net Income Athira Pharma, Inc.|ATHA - Price to Earnings Ratio|Projected Price to Earnings Athira Pharma Corp|ATHA - PEG Multiple|EV/EBITDA Multiple Athira|ATHA - Operating profit before deduction of amortization|Earnings per share for the trailing year Athira Pharma|ATHA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months athira.com|ATHA - Earnings per share growth in current year|Projected earnings per share growth rate for next year Athira Pharma, Inc.
- total revenue and sales volume data:
Fundamental company analysis:Athira Pharma Inc - ATHA
When assessing the asset quality of Athira Pharma, Inc. (ATHA), it is essential to analyze the relationship between market value and earnings dynamics. The P/E-to-growth multiplier trend compares the current P/E ratio to the rate of revenue increase, where a value below one indicates undervaluation. For this developer of Alzheimer's disease treatments, this metric reflects market confidence in the success of neural connection regeneration. Investors should interpret a decline in this indicator as an increase in return potential, which allows for the timely identification of undervalued capital within the neurology sector.
Competing companies
Company Value to Earnings Growth Ratio BIIB|PEG Multiple NBIX (Neurocrine Biosciences Inc)|Growth-Adjusted Payback Ratio RGC|Axsome Therapeutics - PEG Multiple|Growth-Adjusted Market Cap to Net Income acadia-pharm.com ACAD|Xenon (XENE) - Price/Earnings to Growth Ratio|Viking Therapeutics Inc - Growth-Adjusted Payback Ratio|SUPN (Supernus Pharma) - PEG Multiple|PEG Multiple Catalyst Corp|Price/Earnings to Growth Multiple DNLI (Denali Therapeutics)|HRMY (harmonybiosciences.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Biohaven BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Market Cap to Earnings and Growth Ratio|Trevi Pharma - PEG Multiple|Growth-Adjusted Payback Ratio PRAX (Praxis Corp)|AVXL: PEG Multiple|ceribell.com (CBLL) - PEG Multiple|Price/Earnings to Growth Ratio Prothena Corporation plc|ALEC: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Annexon Inc. (ANNX)|Price/Earnings to Growth Multiple omeros.com OMER|PEG Multiple NGNE (Neurogene Inc.)|PEG Multiple acimmune.com ACIU|VYGR: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio NMRA (Neumora)|SCLX: PEG Multiple|TVGN - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Alpha Cognition Inc|Growth-Adjusted P/E Ratio CGTX (cogrx.com)|PEG Multiple IKT|Price/Earnings to Growth Multiple Cassava Sciences Inc SAVA|Assertio - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income Coya Therapeutics Inc (COYA)|VistaGen Therapeutics Inc - PEG Multiple|OVID - PEG Multiple|ABOS (Acumen Pharmaceuticals, Inc.) - Price/Earnings to Growth Multiple|CRVO: Company Value to Earnings Growth Ratio|ATHE (Alterity Therapeutics Ltd.) - PEG Multiple|CLNN: Growth-Adjusted Payback Ratio|PEG Multiple PEPG|PEG Multiple jupiterneurosciences.com (JUNS)|Price/Earnings to Growth Ratio Relmada Therapeutics, Inc. RLMD|ANVS: Growth-Adjusted P/E Ratio|Grace Tx - PEG Multiple|Price to Earnings Adjusted for Growth Rate Firefly Neuro|KLTO (anewmeds.com) - Price/Earnings to Growth Multiple|NeuroSense Therapeutics Ltd. (NRSN) - PEG Multiple|Price/Earnings to Growth Ratio Reviva Pharmaceuticals Holdings, Inc.|MTVA: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio NeurAxis, Inc (NRXS)|HSDT - Price to Earnings Adjusted for Growth Rate|PEG Multiple PASG (Passage Bio)|PEG Multiple Neuphoria Therapeutics, Inc. NEUP|NERV: Price/Earnings to Growth Multiple|Addex Therapeutics Ltd. - Company Value to Earnings Growth Ratio|ALZN: PEG Multiple|Cyclerion Therapeutics, Inc. - Growth-Adjusted Payback Ratio|PTIX (Protagenic Therapeutics Inc.) - PEG Multiple|Pasithea (KTTA) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Cortigent, Inc. (CRGT)|ATXI (Avenue Therapeutics Inc.) - Growth-Adjusted Payback Ratio|PEG Multiple BCLI (Brainstorm Cell Therapeutics, Inc.)|PEG Multiple Cara Therapeutics Inc CARA|CHRO: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio ELYM (Eliem Therapeutics)|intracellulartherapies.com (ITCI) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio LBPH (Longboard Pharmaceuticals Inc)|MRNS (Marinus) - PEG Multiple|NKGN: Growth-Adjusted Payback Ratio|PEG Multiple NRBO|PEG Multiple sagerx.com (SAGE)|Price/Earnings to Growth Ratio Synaptogenix SNPX|Growth-Adjusted Payback Ratio TRVN|VIGL - Price/Earnings to Growth Ratio|Anew Medical Inc. (WENA) - Price/Earnings to Growth Multiple|CERE: PEG Multiple
